Butyric acid (BUT), a short chain fatty acid produced daily by the gut microbiota, has proven beneficial in models of cardiovascular diseases. With advancements in cancer survival, an increasing number of patients are at risk of anticancer drug cardiotoxicity. Here we assess whether the novel BUT derivative phenylalanine-butyramide (FBA) protects from doxorubicin (DOXO) cardiotoxicity, by decreasing oxidative stress and improving mitochondrial function.

The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity

Paparo, Lorella;Trinchese, Giovanna;Aitoro, Rosita;Avagliano, Carmen;Fiordelisi, Antonella;Napolitano, Fabiana;Mercurio, Valentina;Sorriento, Daniela;Ciccarelli, Michele;Bianco, Roberto;Iaccarino, Guido;Abete, Pasquale;Bonaduce, Domenico;Calignano, Antonio;Berni Canani, Roberto;Tocchetti, Carlo G
2019

Abstract

Butyric acid (BUT), a short chain fatty acid produced daily by the gut microbiota, has proven beneficial in models of cardiovascular diseases. With advancements in cancer survival, an increasing number of patients are at risk of anticancer drug cardiotoxicity. Here we assess whether the novel BUT derivative phenylalanine-butyramide (FBA) protects from doxorubicin (DOXO) cardiotoxicity, by decreasing oxidative stress and improving mitochondrial function.
File in questo prodotto:
File Dimensione Formato  
Russo_et_al-2019-European_Journal_of_Heart_Failure.pdf

solo utenti autorizzati

Licenza: Accesso privato/ristretto
Dimensione 10.92 MB
Formato Adobe PDF
10.92 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11588/746202
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 50
social impact